23andMe has created a new therapeutics unit and appointed Dr Richard Scheller chief science officer and head of therapeutics in order to lead it. Dr Scheller retired in December 2014 after 14 years at Genentech where he was the executive vice-president of research and early development.
23andMe appoints ex-Genentech exec to lead new therapeutics unit
23andMe has created a new therapeutics unit and appointed Dr Richard Scheller chief science officer and head of therapeutics in order to lead it. Dr Scheller retired in December 2014 after 14 years at Genentech where he was the executive vice-president of research and early development.
More from Neurological
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.